Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma - Related Studies

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

This study is currently recruiting participants.

Study NCT00082888. Last updated on October 22, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia
		Lymphoma

2	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

3	Interventions listed in this trial
		tipifarnib

4	More general drug interventions related to this trial
		Antineoplastic Agents
		Pharmacologic Actions
		Therapeutic Uses

5	Sponsors listed in this trial
		Mayo Clinic
		National Cancer Institute (NCI)